Scholarlink

Introduction <p>Glucagon-like peptide&#xa0;1 receptor agonists (GLP-1 RAs) are widely used for weight management and type&#xa0;2 diabetes, but reports of reduced skin laxity and volume have raised aesthetic concerns. This study evaluates the first integrated skincare protocol designed for GLP-1 RA users.</p> Methods <p>This 12-week, double-blind, randomized, split-face/split-neck study included 25 GLP-1 RA users (mean age 53.36&#xa0;years) with mild-to-moderate skin aging, including male and female participants with Fitzpatrick skin types II to VI. All participants applied a topical regimen featuring Proxylane and wild fruit flavonoids (Flavo-Proxylane) to one side of the face/neck and a placebo to the other. After 4&#xa0;weeks of topical monotherapy, participants received a single focused ultrasound treatment, followed by an additional 8&#xa0;weeks of topical therapy. Outcomes included blinded image evaluation, 13 clinical grading parameters (via modified Griffiths scale), Global Aesthetic Improvement Scale scores, tolerability, and patient-reported satisfaction.</p> Results <p>All participants completed the study and lost an average of 3.7&#xa0;lb. After 4&#xa0;weeks of Flavo-Proxylane monotherapy, significant improvements were observed for facial skin laxity (− 16%; <i>P</i> &lt; 0.001) and marionette lines (− 5%; <i>P</i> &lt; 0.05), while no significant changes were observed with placebo. By week&#xa0;12, the combined regimen achieved amplified improvements versus baseline, week&#xa0;4, and placebo (all <i>P</i> &lt; 0.001), with total reductions of 44% in skin laxity and 34% in marionette lines. Significant improvements were observed across all 13 clinical parameters. Overall improvement rating favored Flavo-Proxylane, with 94% reporting moderate-to-significant improvement versus 30% for placebo. Flavo-Proxylane treatment was well tolerated, with 84% reporting improved skin appearance and only three mild, self-resolving adverse events.</p> Conclusion <p>This study demonstrates that an integrated regimen with Flavo-Proxylane products and ultrasound may improve aesthetic outcomes in a diverse range of participants undergoing GLP-1 RA treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月4日

查看全文
  • Amir Moradi,
  • Jihee H. Kim,
  • Jemin M. Kim,
  • Hina N. Choudhary,
  • Patricia M. Brieva

摘要

Introduction

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used for weight management and type 2 diabetes, but reports of reduced skin laxity and volume have raised aesthetic concerns. This study evaluates the first integrated skincare protocol designed for GLP-1 RA users.

Methods

This 12-week, double-blind, randomized, split-face/split-neck study included 25 GLP-1 RA users (mean age 53.36 years) with mild-to-moderate skin aging, including male and female participants with Fitzpatrick skin types II to VI. All participants applied a topical regimen featuring Proxylane and wild fruit flavonoids (Flavo-Proxylane) to one side of the face/neck and a placebo to the other. After 4 weeks of topical monotherapy, participants received a single focused ultrasound treatment, followed by an additional 8 weeks of topical therapy. Outcomes included blinded image evaluation, 13 clinical grading parameters (via modified Griffiths scale), Global Aesthetic Improvement Scale scores, tolerability, and patient-reported satisfaction.

Results

All participants completed the study and lost an average of 3.7 lb. After 4 weeks of Flavo-Proxylane monotherapy, significant improvements were observed for facial skin laxity (− 16%; P < 0.001) and marionette lines (− 5%; P < 0.05), while no significant changes were observed with placebo. By week 12, the combined regimen achieved amplified improvements versus baseline, week 4, and placebo (all P < 0.001), with total reductions of 44% in skin laxity and 34% in marionette lines. Significant improvements were observed across all 13 clinical parameters. Overall improvement rating favored Flavo-Proxylane, with 94% reporting moderate-to-significant improvement versus 30% for placebo. Flavo-Proxylane treatment was well tolerated, with 84% reporting improved skin appearance and only three mild, self-resolving adverse events.

Conclusion

This study demonstrates that an integrated regimen with Flavo-Proxylane products and ultrasound may improve aesthetic outcomes in a diverse range of participants undergoing GLP-1 RA treatment.